Alkermes (ALKS) EBIT (QoQ) (2010 - 2026)
Alkermes (ALKS) EBIT (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 138.01% |
| Mar 31, 2026 | -183.09% |
| Dec 31, 2025 | -34.77% |
| Sep 30, 2025 | -4.19% |
| Jun 30, 2025 | 574.14% |
| Mar 31, 2025 | -91.52% |
| Dec 31, 2024 | 55.30% |
| Sep 30, 2024 | -4.67% |
| Jun 30, 2024 | 153.72% |
| Mar 31, 2024 | -20.72% |
| Dec 31, 2023 | -38.75% |
| Sep 30, 2023 | -68.29% |
| Jun 30, 2023 | 2,663.52% |
| Mar 31, 2023 | -109.49% |
| Dec 31, 2022 | 290.62% |
| Sep 30, 2022 | -75.99% |
| Jun 30, 2022 | -29.61% |
| Mar 31, 2022 | -120.54% |
| Dec 31, 2021 | 758.30% |
| Sep 30, 2021 | -544.67% |